Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704288 · ClinicalTrials.gov registry record · Phase 2
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
A Phase 2 study, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT00704288: Completed Phase 2 study, sponsored by Exelixis.
NCT00704288 is a Phase 2 study that has completed, run by Exelixis. The registered enrollment target is 222 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00704288, a Phase 2 study, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
Primary Outcome
Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features
Interventions
- DRUG XL184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00704288 record still lists
NCT00704288 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 1 intervention - of which XL184 is the first listed.
NCT00704288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00704288 about?
NCT00704288 is a clinical study titled "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme". The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth ...
What is the current status of trial NCT00704288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2008-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00704288?
The interventions under investigation include: XL184 (DRUG).
Who is sponsoring clinical trial NCT00704288?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00704288's enrollment target sits among peer trials
222 274th of 2000 higher than 1,726 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia